Tonix Pharmaceuticals Files 8-K

Ticker: TNXP · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1430306

Sentiment: neutral

Topics: corporate-update, filing

Related Tickers: TNXP

TL;DR

TONIX filed an 8-K, basic corporate info updated, stock still on NASDAQ.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on February 6, 2025, reporting on its corporate activities. The filing confirms the company's principal executive offices are located at 26 Main Street, Chatham, New Jersey 07928, and its common stock trades under the symbol TNXP on The NASDAQ Capital Market. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing serves as a routine update for investors regarding Tonix Pharmaceuticals' corporate information and stock listing details.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not contain information that inherently increases or decreases risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about Tonix Pharmaceuticals Holding Corp., including its corporate address and stock exchange listing.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 6, 2025.

Where are Tonix Pharmaceuticals Holding Corp.'s principal executive offices located?

Tonix Pharmaceuticals Holding Corp.'s principal executive offices are located at 26 Main Street, Chatham, New Jersey 07928.

What is the trading symbol for Tonix Pharmaceuticals Holding Corp.'s common stock?

The trading symbol for Tonix Pharmaceuticals Holding Corp.'s common stock is TNXP.

On which exchange is Tonix Pharmaceuticals Holding Corp.'s common stock registered?

Tonix Pharmaceuticals Holding Corp.'s common stock is registered on The NASDAQ Capital Market.

Filing Stats: 1,415 words · 6 min read · ~5 pages · Grade level 12.5 · Accepted 2025-02-06 08:06:04

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On February 6, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced positive topline results from a Phase 1, single ascending dose trial of its TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb) product candidate in healthy participants. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The Company updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On February 6, 2025, the Company announced positive topline results from a Phase 1, single ascending dose trial of TNX-1500 in healthy participants. The objectives of the Phase 1 trial were to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500, as well as to support dosing in a planned Phase 2 trial in kidney transplant recipients. First generation anti-CD40L mAb ruplizumab showed activity in modulating autoimmunity and rejection in allo- and xeno-transplantation, but was limited by an increased risk of thrombosis. The Company created TNX-1500, a next generation anti-CD40L mAb, by reengineering the Fc region of ruplizumab to preserve activity with improved safety. The Company believes that the results of the Phase 1 study indicate that TNX-1500 has met these design objectives, and that the results of this study and prior animal studies indicate that TNX-1500 is potentially best-in-class among anti-CD40L mAbs in development. Top line results from the TNX-1500 Phase 1 study showed that TNX-1500 at the 10 mg/kg and 30 mg/kg doses blocked both the primary and secondary antibody responses to a test antigen. The pharmacokinetic data support monthly dosing at doses of 10 mg/kg or above. The Company believes that TNX-1500 has the potential to prevent organ transplant rejection and improve graft survival with reduced long-term toxicity burden relative to current immunosuppressive regimens." Methods and Topline Results Dosing : TNX-1500 solution was infused intravenously over a period of one hour to achieve doses of 3 mg/kg, 10 mg/kg, and 30 mg/kg. Participants were observed in the clinic for one day and followed with periodic clinic visits to Day 120. Keyhole Limpet Hemocyanin (KLH) Challenge : To evaluate the immune modulation potency of TNX-1500, participants received an antigen challenge with KLH (Immucothel ) administered subcutaneously (SC) on Day 2 and Day 29 of the study. Disposition : A to

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, February 6, 2025 99.02 Corporate Presentation by the Company for February 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: February 6, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing